Form 4: Vor Biopharma CEO Robert Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vor Biopharma CEO Robert Ang disposed of 2,751 shares of common stock on May 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.
Summary
- On May 1, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations associated with the settlement of restricted stock units.
- The shares were sold at a price of $1.77 per share.
- Following the transaction, Ang directly owns 812,729 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice among executives.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of transaction: Robert Ang disposed of 2,751 shares of common stock. |
| 05/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.